English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 24592830      Online Users : 364
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32518

    標題: Risk of ischaemic stroke in thyrotoxic atrial fibrillation
    作者: Zhih-Cherng Chen(陳志成)
    Nan-Chun Wu(吳南鈞)
    Chang, Chia-Li
    Chung-Han Ho(何宗翰)
    Liao, Chia-Te
    Chun-Yen Chiang(蔣俊彥)
    Chang, Wei-Ting
    貢獻者: Chi Mei Med Ctr, Dept Cardiol
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Chi Mei Med Ctr, Dept Cardiovasc Surg
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    Chi Mei Med Ctr, Dept Med Res
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    Natl Cheng Kung Univ, Coll Med, Inst Clin Med
    關鍵字: Atrial fibrillation
    日期: 2019-10
    上傳時間: 2020-07-29 13:48:15 (UTC+8)
    出版者: WILEY
    摘要: Objective Atrial fibrillation (AF) is the most common cardiac complication of thyrotoxicosis and is strongly implicated in thromboembolic events. However, the incidence of stroke in thyrotoxic AF remains unclear. Herein, we aimed to investigate the risks of mortality and ischaemic stroke between patients with thyrotoxic AF and nonthyrotoxic AF. Designs and Methods From Taiwan's National Health Insurance Research Database, 1868 patients with the concomitant diagnoses of AF and thyrotoxicosis identified between 2001 and 2010 were compared to 7472 patients with nonthyrotoxic AF using propensity score matching for age, sex and comorbidities. Results There was no significant difference in either CHA(2)DS(2)-VASc score or anticoagulant usage between the groups. Alternatively, the thyrotoxic group contained more beta-blocker/digoxin users, whereas the nonthyrotoxic group contained more statin users. Patients with thyrotoxic AF exhibited lower risks of all-cause mortality (HR: 0.66, CI: 0.59-0.73, P < .0001) and ischaemic stroke (HR: 0.73, CI: 0.64-0.84, P < .0001) than those with nonthyrotoxic AF, especially thyrotoxic patients with CHA(2)DS(2)-VASc scores >= 1. Comorbidities, including diabetes, hyperlipidaemia, hypertension and coronary artery disease, contributed to all-cause mortality in patients with nonthyrotoxic AF; however, this effect was diminished in thyrotoxic AF. Conclusions Patients with thyrotoxicosis and AF have a lower risk of stroke than patients with nonthyrotoxic AF. Treatment for thyrotoxicosis is also crucial as the prescription of anticoagulants based on CHA2DS2-VASc scores.
    關聯: Clinical Endocrinology, v.91, n.4, pp.561-570
    Appears in Collections:[藥學系(所)] 期刊論文
    [醫務管理系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1111-cen.14061.pdf643KbAdobe PDF356View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback